Incyte Corporation (INCY) Ownership Up in Latest Report from Bb Biotech Ag

Marco Green
November 15, 2017

Incyte Pharm now has $21.96 billion valuation. The stock decreased 1.95% or $2.09 during the last trading session, reaching $105.12. The volume of 1.06 Million shares climbed down over an trading activity of 432.95 Million shares. Incyte Corporation (NASDAQ:INCY) has risen 72.84% since November 13, 2016 and is uptrending. It has outperformed by 56.14% the S&P500.

Incyte Genomics Incorporated (NASDAQ:INCY) had an increase of 10.64% in short interest. GTY's SI was 438,100 shares in November as released by FINRA. Its up 10.91% from 395,000 shares previously. The SI to Incyte Genomics Incorporated's float is 3.82%. About 2.01M shares traded or 14.20% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since November 14, 2016 and is uptrending. It has outperformed by 19.47% the S&P500.

Among 4 analysts covering Getty Realty Corp. (NYSE:GTY), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 65% are positive. The company was maintained on Friday, July 28 by Canaccord Genuity. (NYSE:GTY) on Monday, September 7 to "Sell" rating. The firm earned "Outperform" rating on Monday, January 23 by Credit Suisse. The rating was maintained by Argus Research on Tuesday, August 18 with "Buy".

Getty Realty Corp.is a real estate investment trust. Incyte Corporation now has a P/E ratio of N/A and market cap is 22.10B. It has a 24.21 P/E ratio. As of June 30, 2017, the Company's 825 properties were located in 26 states across the United States and Washington, District of Columbia.

Investors sentiment decreased to 1.02 in 2017 Q2. Its up 0.21, from 1.13 in 2017Q1. It is negative, as 11 investors sold Getty Realty Corp. shares while 39 reduced holdings. 13 funds opened positions while 50 raised stakes. Essex Financial Inc holds 0.08% or 15,603 shares. Thrivent For Lutherans invested in 16,261 shares or 0% of the stock. (NYSE:GTY). Price Michael F invested 0.11% of its portfolio in Getty Realty Corp. Synovus Financial Corporation reported 9,333 shares. (NASDAQ:INWK). National Bank Of Mellon holds 189,045 shares. Ithaka Group Inc Ltd Liability Corporation reported 91,084 shares stake. Shine Advisory Svcs has 168 shares for 0.01% of their portfolio. Commerzbank Aktiengesellschaft Fi reported 0.38% stake. Rothschild Asset Mngmt Inc stated it has 500,051 shares. Peak6 Invs Lp holds 0.03% or 44,990 shares in its portfolio. Oppenheimer Holdings, Inc. reissued a "hold" rating and issued a $135.00 price objective on shares of Incyte Corporation in a report on Sunday, September 10th. Therefore 83% are positive. Finally, Evercore ISI started coverage on Incyte Corporation in a report on Wednesday, August 16th.

Investment analysts at BMO Capital now has a $166 PT on Incyte (NASDAQ:INCY). The stock of Incyte Corporation (NASDAQ:INCY) has "Buy" rating given on Tuesday, August 18 by Vetr. Recently, investment analysts covering the stock have updated the mean rating to 1.9. Capital Guardian Trust Company sold 783,596 shares as the company's stock rose 9.08% with the market. BMO Capital Markets lowered the price target of the stock on October 26 changing the price objective from $163.00 to $162.00 with a rating of "Outperform". The firm has "Buy" rating by Zacks given on Wednesday, August 12. Incyte has $18000 highest and $85 lowest target.

On October 25, 2017 J P Morgan Chase & Co reiterated a "Buy" rating on the company. Nomura has "Buy" rating and $146 target.

Investors sentiment decreased to 1.02 in Q2 2017. 0 analysts call it Underweight, while 1 think it is Overweight. The original version of this piece can be read at https://stocknewstimes.com/2017/11/14/david-w-gryska-sells-3915-shares-of-incyte-corporation-incy-stock.html. 67 funds opened positions while 153 raised stakes. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.11. (NASDAQ:INWK). Northern Trust Corporation accumulated 0% or 749,922 shares. Ls Inv Advsr Lc has 5,595 shares.

Here are some institutional investors who have increased or decreased their stake in (INCY).

10,996 are owned by Gateway Advisers Ltd Liability Corp. Kistler has invested 0% in Incyte Corporation (NASDAQ:INCY). 2,428 were accumulated by Parkwood Lc. Schwab Charles Mngmt Incorporated owns 519,765 shares. The Texas-based Capstone Asset Management Comm has invested 0.07% in Incyte Corporation (NASDAQ:INCY). 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported. Fifth Third Bancorp now owns 1,678 shares of the biopharmaceutical company's stock worth $134,000 after buying an additional 234 shares during the last quarter. Moreover, First In has 0.07% invested in Celgene Corporation (NASDAQ:CELG) for 840 shares. Alpha Windward Limited Company has invested 0.14% in Celgene Corporation (NASDAQ:CELG).

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER